Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L31 pseudogene 32 (RPL31P32) is a non-functional genomic sequence in humans derived from the ribosomal protein L31 gene. As a pseudogene, RPL31P32 does not produce active protein and is not implicated as a therapeutic target, biological marker, or disease-related entity[1][8][3]. Unlike its parental gene (RPL31), which encodes a cytoplasmic ribosomal protein involved in protein synthesis, RPL31P32 is considered a processed pseudogene with no evidence of protein-coding capability or biological role. There are no drugs, biomarkers, or safety issues associated with RPL31P32.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L31 pseudogene 32 (RPL31P32).